ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

MiR-4284 inhibits sensitivity to paclitaxel in human ovarian carcinoma SKOV3ip1 and HeyA8 cells by targeting DMC1

Sun, Dongyan*; Shang, Di; Miao, Pan; Jiang, Zhihe; Chen, Yanling; Gao, Jianwuhan univ sci & technol; yangtze univ
Anti-Cancer Drugs2022-9DOI: 10.1097/CAD.0000000000001314
2被引3阅读
引用收藏
分享

摘要

An increasing number of studies have confirmed that microRNAs (miRNAs) are involved in various biological processes, including tumor growth and drug resistance. MiR-4284 has been proved to be abnormally regulated in several cancers, but the function of miR-4284 in ovarian carcinoma (OC) is unclear. Paclitaxel resistance is a key obstacle in OC treatment. Here, the role of miR-4284 in cell sensitivity to paclitaxel in OC was investigated. Two OC cell lines (SKOV3ip1 and HeyA8) were utilized for the establishment of paclitaxel-resistant cell lines. Reverse transcription-quantitative PCR (RT-qPCR) was applied to analyze the levels of miR-4284 and potential mRNAs in OC cell lines. Western blotting was performed to evaluate the levels of DNA meiotic recombinase 1 (DMC1) protein and cell cycle-associated proteins. Identification of the relationship between miR-4284 and DMC1 was achieved by luciferase reporter assay. CCK-8 and flow cytometry assays were utilized for evaluating the impact of miR-4284 on the malignant characteristics of paclitaxel-resistant OC cells. MiR-4284 was upregulated in paclitaxel-resistant OC cell lines and correlated with an adverse prognosis in OC patients. Depletion of miR-4284 suppressed cell proliferation and cell cycle progression of paclitaxel-resistant OC. MiR-4284 targeted DMC1 which was downregulated in paclitaxel-resistant cells and reversed the inhibitory influence of miR-4284 silencing on the malignant characters of paclitaxel-resistant OC cells. MiR-4284 targets DMC1 to suppress sensitivity to paclitaxel in human OC cells.

学科与关键词

关键词
DMC1miR-4284ovarian carcinomapaclitaxel resistance
相关
加载中…
  • MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway
    Zhang, Li-ying; Yu, Jia-ying; Leng, Yan-long; Zhu, Ran-ran; Liu, Hong-xian; Wang, Xin-yu; Yang, Ting-ting; Guo, Yi-ning; Tang, Jing-ling*; Zhang, Xin-chen*Cancer Gene Therapy, 2022, 29(6): 770-783.被引 5
  • CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression
    Huang, Chunyan; Qin, Li; Chen, Sailan; Huang, Qin*Anti-Cancer Drugs, 2023, 34(3): 395-404.被引 2
  • Radix ranunculus temate saponins sensitizes ovarian cancer to Taxol via upregulation of miR-let-7b
    You, Keli; Liu, Yuejun; Chen, Le; Ye, Haiyan*; Lin, Wumei*Experimental and Therapeutic Medicine, 2022, 23(5): 315.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Anti-Cancer Drugs
发表日期
2022-09
卷期
第 33 卷, 第 8 期
页码
701-709
DOI
10.1097/CAD.0000000000001314
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
School of Medicine, Wuhan University of Science and Technology [220940015]; 4th Wuhan Young and Middleaged Backbone Talent of Medical Training Project

作者

  • S

    Sun, Dongyan (通讯) (第一作者)

  • S

    Shang, Di

    wuhan univ sci & technol

查看全部 6 位作者收起作者
  • M

    Miao, Pan

    yangtze univ

  • J

    Jiang, Zhihe

    wuhan univ sci & technol

  • C

    Chen, Yanling

    wuhan univ sci & technol

  • G

    Gao, Jian

    wuhan univ sci & technol

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417